Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.50 USD
Change Today 0.00 / 0.00%
Volume 20.0K
ENUM On Other Exchanges
As of 5:20 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

enumeral biomedical holdings (ENUM) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/10/14 - $1.90
52 Week Low
05/21/15 - $0.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

enumeral biomedical holdings (ENUM) Related Businessweek News

No Related Businessweek News Found

enumeral biomedical holdings (ENUM) Details

Enumeral Biomedical Holdings, Inc. engages in discovering and developing antibody immunotherapies that help the immune system fight cancer and other diseases. It is developing antibodies against a number of classes of immunomodulatory proteins expressed on the surface of cells of the immune system for the treatment of cancer, autoimmune, and inflammatory diseases. Enumeral Biomedical Holdings, Inc. has a collaboration agreement with Merck Sharp & Dohme Corp.; and research contract with the National Cancer Institute. Enumeral Biomedical Holdings, Inc. was founded in 2009 and is based in Cambridge, Massachusetts.

enumeral biomedical holdings (ENUM) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $174.6K
Co-Founder and Executive Chairman
Total Annual Compensation: $167.4K
Chief Accounting Officer, Vice President of F...
Total Annual Compensation: $85.4K
Vice President of Business Development
Total Annual Compensation: $171.3K
Compensation as of Fiscal Year 2014.

enumeral biomedical holdings (ENUM) Key Developments

Enumeral Biomedical Holdings, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter Ended June 30, 2015

Enumeral Biomedical Holdings, Inc. reported unaudited consolidated earnings results for the second quarter ended June 30, 2015. For the quarter, the company's revenue was $381,313. This increase in revenue is attributable to the Company’s collaboration agreement with Merck and its grant from the National Cancer Institute. Loss from operations was $2,915,870 compared to $1,133,728 a year ago. Net loss before income taxes was $29,019 compared to $1,206,429 a year ago. Net loss was $29,019 compared to $1,206,429 a year ago. Diluted loss per common share was $0.00 compared to $0.06 a year ago. This decrease was primarily due to an increase in the change in fair value of derivative liabilities of $2,878,847 and an increase in revenues of $381,313, offset by an increase of $2,163,455 in research and development and general and administrative expenses.

Enumeral Biomedical Holdings, Inc. Appoints Robert J. Easton to its Board of Directors

Enumeral Biomedical Holdings, Inc. announced that it has appointed Robert J. Easton to its Board of Directors. Mr. Easton is a recognized leader in the life sciences and healthcare industries, having led strategy development and supervised opportunity assessments for hundreds of clients across the globe, including large and specialty pharmaceutical companies, early-stage and publicly traded biopharmaceutical companies, and diagnostics businesses. Mr. Easton currently serves as Co-Chairman of Bionest Partners, Inc. Mr. Easton replaces Daniel B. Wolfe, Ph.D., who has stepped down after serving on the Enumeral board since 2009.

Enumeral Biomedical Holdings, Inc. Announces Recent Progress in its PD-1 Antibody Program

Enumeral Biomedical Holdings, Inc. announced recent progress in its PD-1 antibody program. Enumeral also provided an update on the progress of additional programs in the company's R&D pipeline, including its TIM-3 antibody program. Enumeral has identified antibodies that appear to bind to PD-1 in a manner different from that of currently marketed anti-PD1 antibodies, while retaining activity in cell-based assays. The company has isolated more than 300 sequences of PD-1 binding antibodies from primary B cells in its PD-1 program. The company's bioinformatics analysis of sequences indicates that these antibodies are diverse, falling into 26 distinct clades, or families, that bind to PD-1. Enumeral has advanced six lead clones into pre-clinical characterization, four of which are undergoing humanization. The company anticipates that the humanization process will be completed by the end of the third quarter of 2015, which will enable initiation of cell line development for IND-enabling studies. In Enumeral's TIM-3 program, the company has isolated 180 screening hits and has sequenced 88 TIM-3 binding antibodies to date, and its screening efforts are ongoing. Enumeral's bioinformatics analysis indicates desirable diversity, with the antibodies falling into 17 unique clades that bind to TIM-3. Enumeral plans to apply its unique approach to cellular immune response profiling to further understand the utility of these different antibodies for modulation of different TILs. The company believes antibodies that block TIM-3 may potentiate anti-cancer immune responses, either as a monotherapy or in combination with other therapies, including other immune checkpoint-targeted drugs. The company currently anticipates nominating lead clones by the end of the third quarter 2015, and beginning the humanization process by the end of this year. Enumeral also noted that it is engaged in ongoing antibody screening in its LAG-3, OX40, and VISTA programs. Using human biopsy samples, the company intends to validate antibody blocking effects against these targets, and then assess potential monotherapy or combination therapy regimens using proprietary antibodies.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENUM:US $0.50 USD 0.00

ENUM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ENUM.
View Industry Companies

Industry Analysis


Industry Average

Valuation ENUM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 33.6x
Price/Book 28.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 22.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENUMERAL BIOMEDICAL HOLDINGS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at